MedTrace Logo

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

NCT05411133 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-03-19

No results posted yet for this study

Summary

This study aims to find out:

1. The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker.
2. To find out how study drug is broken down in the body
3. To know the effects of the study drug on the tumor.

Conditions

Interventions

DRUG

Cabotamig (ARB202)

Cabotamig (ARB202), Atezolizumab

Sponsors & Collaborators

  • Arbele Pty Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-30
Primary Completion
2025-07-23
Completion
2025-07-23
FDA Drug
Yes

Countries

  • Australia
  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05411133 on ClinicalTrials.gov